Robert J. Motzer, MD
Three game-changing immunotherapy trials have transformed the treatment paradigm in frontline clear cell renal cell carcinoma (RCC). At the 37th Annual
, Robert J. Motzer, MD, Memorial Sloan Kettering Cancer Center, compared the findings from the three studies.
The 3 phase III randomized trials all had a control arm of single-agent sunitinib (Sutent): the CheckMate 214 trial2
(n = 1096) exploring nivolumab (Opdivo) plus ipilimumab (Yervoy); the KEYNOTE-426 trial3
(n = 861) assessing pembrolizumab (Keytruda) plus the tyrosine kinase inhibitor (TKI) axitinib (Inlyta); and JAVELIN Renal 1014
(n = 886), which explored avelumab (Bavencio) plus axitinib.
... to read the full story